Skip to main content

Bimekizumab's Favorable Safety Profile in Psoriasis

May 11, 2022 5:54 pm

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

JAMA Dermatology published this pooled analysis of 8 randomized clinical (phase 2 or phase 3) trials included 1789 patients with moderate to severe plaque psoriasis treated with BMK and followed for up to 2 years.  The primary outcome in this analsysis was treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs leading to treatment discontinuation are reported using exposure-adjusted incidence rates (EAIRs) per 100 person-years.

From a total of 1789 BMK patients, there was a total bimekizumab exposure of 3109.7 person-years.

Adverse events (TEAEs) occurred at rate (EAIR) of 202.4 per 100 person-years but did not increase with longer duration of bimekizumab exposure. Common AE included nasopharyngitis (19.1/00PY) oral candidiasis (12.6/100PY), and upper respiratory tract infection (8.9/100PY).

Oral candidiasis with BMK (a dual IL-17A/F inhibitor) appears to be more common that that seen with currently marketed IL-17 inhibitors.  Fortunately, most candidiasis events were mild or moderate, decrease over time and was mostly oral mucocutaneous candidiasis with no cases of invasive candidiasis. A minority of affected patients had repeat candidiasis episodes and most were treated with nystatin and/or fluconazole (median duration of antifungal was 12 days). Only 3 patients (0.2%) with oral candidiasis discontinued BMK.  There were few cases of other fungal infections.

Other adverse events of concern were infrequent and included:

  • Inflammatory bowel disease (0.1 per 100 person-years. There was a total of 4 cases (2 Crohn disease, 1 colitis, and 1 ulcerative colitis);
  • Adjudicated suicidal ideation and behavior (0.0 per 100 person-years);
  • Adjudicated major adverse cardiac events (0.5 per 100 person-years)

Bimekizumab is a selective inhibitor of both IL-17A and IL-17F.14-16 and in clinical trials has previously demonstrated superior efficacy compared to placebo, ustekinumab (anti–IL-12/23), adalimumab (anti-tumor necrosis factor), and secukinumab (anti–IL-17A) in patients with moderate to severe plaque psoriasis.


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject